Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Inks “Transformational” Licensing Agreement With Onco Therapies To Extend Reach In Emerging Markets

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal also extends GSK’s interest in branded generics.

You may also be interested in...



GSK/Aspen Deal Indicates Rising Interest In Emerging Markets Beyond ‘BRIC’

Aspen gains eight specialist medicines and German manufacturing facility from GlaxoSmithKline:

GSK/Aspen Deal Indicates Rising Interest In Emerging Markets Beyond ‘BRIC’

Aspen gains eight specialist medicines and German manufacturing facility from GlaxoSmithKline:

Pharma's Strategic Divide: Focus or Diversify

It looks like the biggest strategic gulf in the industry: focus or diversify? If the CEO thinks he can't rely on R&D to grow his way out of the industry's revenue hole, get ready to live alongside generics and OTC businesses--though he'll downplay to investors the risks of managing different businesses by stressing the commonalities with the core branded efforts and probably won't move into wholly non-pharma businesses. If he's still committed to R&D--get ready for diversification of other sorts, and some pretty clever financial tactics.

Topics

UsernamePublicRestriction

Register

PS068143

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel